ProStrakan offers patch to prevent nausea and vomiting

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

Sancuso (granisetron transdermal system) is now available by prescription in the U.S. for patients with chemotherapyinduced nausea and vomiting. The patch continuously releases granisetron into the bloodstream for up to five consecutive days.

Sancuso (granisetron transdermal system) is now available by prescription in the U.S. for patients with chemotherapyinduced nausea and vomiting. The patch continuously releases granisetron into the bloodstream for up to five consecutive days.

The most common adverse reaction is constipation. No clinically relevant drug interactions have been reported in studies with Sancuso, according to the company.

Aranesp/IV iron aids chemo-induced anemia

Adding iron intravenously to darbepoetin alfa elicits a better response to chemotherapy-induced anemia than when darbepoetin alfa is taken alone, according to the results of a phase II trial presented at ESMO 2008.

Baltimore-based hematologist  Michael Auerbach, MD, and colleagues studied 238 patients with lung, gastrointestinal, breast, and other tumor types. Two doses of darbepoetin alfa (Aranesp) were compared: 500 mcg vs 300 mcg every three weeks along with IV iron or no IV iron. Target hemoglobin was at least 11 g/dL.

The researchers found 78% of 118 patients given 500 mcg of darbepoetin and 75% of 112 patients given 300 mcg reached this goal, as did 82% of 110 patients given IV iron versus 72% of 117 patients who did not receive IV iron. However, more research is needed to determine safety, commented Matti S. Aapro, MD, of the Institut Multidisciplinaire d’Oncologie in Genolier, Switzerland.

Recent Videos
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
2 experts are featured in this series.
2 experts are featured in this series.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Related Content